Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87865
Title:
Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement.
Authors:
Leese, G P; Wallymahmed, M; Wieringa, Gilbert E; VanHeyningen, C; MacFarlane, I A
Abstract:
OBJECTIVE: To determine whether apo E phenotype influences changes in lipid profiles induced by growth hormone replacement in growth hormone (GH)-deficient adults. DESIGNS: Patients were treated for 6 months with recombinant human GH (hGH), given in a dose of 0.125 U/kg per week for 4 weeks followed by 0.25 U/kg per week thereafter. The effects on serum lipids and the influence of apo E phenotype were examined. METHODS: Thirty patients (aged 35.1+/-11.8 years: mean +/- S.D.) with adult growth hormone deficiency with included in the study. Fasting serum samples were analysed for apo E phenotype total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, lipoprotein (a) (Lp(a)) and IGF-I. Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedwald formula. RESULTS: Six months of replacement treatment with hGH resulted in a reduction in HDL-cholesterol from 0.90+/-0.10 to 0.68+/-0.08 mmol/l (P<0.01), and a small, non-significant reduction in total cholesterol from 6.14+/-0.40 to 5.99+/-0.35 mmol/l (P = 0.06). There was no significant change in the other lipid parameters. The decrease in HDL-cholesterol concentration was greater in patients carrying the apo E2 allele (0.40+/-0.07 mmol/l, P<0.05) than in patients homozygous for the apo E3 allele (0.23+/-0.04 mmol/l) and patients carrying the apo E4 allele (0.15+/-0.36 mmol/l). Patients with the apo E4 allele had lower baseline cholesterol concentrations than patients lacking the apo E4 allele, and this persisted after treatment with hGH (P<0.05). CONCLUSIONS: Apo E phenotype may be a determining factor in the response of HDL-cholesterol to hGH in GH-deficient adults.
Affiliation:
Department of Endocrinology, Ninewells Hospital, Dundee, UK.
Citation:
Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. 1999, 140 (2):174-9 Eur. J. Endocrinol.
Journal:
European Journal of Endocrinology
Issue Date:
Feb-1999
URI:
http://hdl.handle.net/10541/87865
DOI:
10.1530/eje.0.1400174
PubMed ID:
10069664
Type:
Article
Language:
en
ISSN:
0804-4643
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLeese, G Pen
dc.contributor.authorWallymahmed, Men
dc.contributor.authorWieringa, Gilbert Een
dc.contributor.authorVanHeyningen, Cen
dc.contributor.authorMacFarlane, I Aen
dc.date.accessioned2009-12-14T15:06:02Z-
dc.date.available2009-12-14T15:06:02Z-
dc.date.issued1999-02-
dc.identifier.citationApo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. 1999, 140 (2):174-9 Eur. J. Endocrinol.en
dc.identifier.issn0804-4643-
dc.identifier.pmid10069664-
dc.identifier.doi10.1530/eje.0.1400174-
dc.identifier.urihttp://hdl.handle.net/10541/87865-
dc.description.abstractOBJECTIVE: To determine whether apo E phenotype influences changes in lipid profiles induced by growth hormone replacement in growth hormone (GH)-deficient adults. DESIGNS: Patients were treated for 6 months with recombinant human GH (hGH), given in a dose of 0.125 U/kg per week for 4 weeks followed by 0.25 U/kg per week thereafter. The effects on serum lipids and the influence of apo E phenotype were examined. METHODS: Thirty patients (aged 35.1+/-11.8 years: mean +/- S.D.) with adult growth hormone deficiency with included in the study. Fasting serum samples were analysed for apo E phenotype total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, lipoprotein (a) (Lp(a)) and IGF-I. Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedwald formula. RESULTS: Six months of replacement treatment with hGH resulted in a reduction in HDL-cholesterol from 0.90+/-0.10 to 0.68+/-0.08 mmol/l (P<0.01), and a small, non-significant reduction in total cholesterol from 6.14+/-0.40 to 5.99+/-0.35 mmol/l (P = 0.06). There was no significant change in the other lipid parameters. The decrease in HDL-cholesterol concentration was greater in patients carrying the apo E2 allele (0.40+/-0.07 mmol/l, P<0.05) than in patients homozygous for the apo E3 allele (0.23+/-0.04 mmol/l) and patients carrying the apo E4 allele (0.15+/-0.36 mmol/l). Patients with the apo E4 allele had lower baseline cholesterol concentrations than patients lacking the apo E4 allele, and this persisted after treatment with hGH (P<0.05). CONCLUSIONS: Apo E phenotype may be a determining factor in the response of HDL-cholesterol to hGH in GH-deficient adults.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAlleles-
dc.subject.meshApolipoprotein E2-
dc.subject.meshApolipoprotein E3-
dc.subject.meshApolipoprotein E4-
dc.subject.meshApolipoproteins E-
dc.subject.meshCholesterol, HDL-
dc.subject.meshFemale-
dc.subject.meshHormone Replacement Therapy-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshLipids-
dc.subject.meshMale-
dc.subject.meshPhenotype-
dc.subject.meshRecombinant Proteins-
dc.titleApo E phenotype and changes in serum lipids in adult patients during growth hormone replacement.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Ninewells Hospital, Dundee, UK.en
dc.identifier.journalEuropean Journal of Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.